Aichi Cancer Center

Futó vizsgálatok

• Toboroz

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· 2/3. fázis· Forrás

• Toboroz

  A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

  NCT07405151· 1/2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· 3. fázis· Forrás

• Toboroz

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· 3. fázis· Forrás

• Toboroz

  A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· 1. fázis· Forrás

• Toboroz

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· 3. fázis· Forrás

• Toboroz

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· 3. fázis· Forrás

• Toboroz

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· 3. fázis· Forrás

• Toboroz

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· 3. fázis· Forrás

• Toboroz

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· 3. fázis· Forrás

• Toboroz

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· 1/2. fázis· Forrás

• Toboroz

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· 3. fázis· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

  NCT07023289· 2. fázis· Forrás

• Toboroz

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· 1. fázis· Forrás

• Toboroz

  Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  NCT06780111· 1/2. fázis· Forrás

• Toboroz

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· 3. fázis· Forrás

• Toboroz

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· 1/2. fázis· Forrás

• Toboroz

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

  NCT06820463· 2. fázis· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· 3. fázis· Forrás

• Toboroz

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· 3. fázis· Forrás

• Toboroz

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· 3. fázis· Forrás

• Toboroz

  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  NCT06772623· 1/2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

  NCT06780137· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· 3. fázis· Forrás

• Fut, nem toboroz

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· 1. fázis· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· 2. fázis· Forrás

• Toboroz

  A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

  NCT06699212· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT06628310· 2. fázis· Forrás

• Toboroz

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· 2. fázis· Forrás

• Toboroz

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· 3. fázis· Forrás

• Fut, nem toboroz

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· 1. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· 3. fázis· Forrás

• Toboroz

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· 3. fázis· Forrás

• Toboroz

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· 3. fázis· Forrás

• Toboroz

  Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  NCT06422143· 3. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· 1. fázis· Forrás

• Fut, nem toboroz

  A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

  NCT06390995· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

  NCT06356311· 3. fázis· Forrás

• Fut, nem toboroz

  S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  NCT06188702· 1/2. fázis· Forrás

• Toboroz

  A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  NCT06385080· 1/2. fázis· Forrás

• Fut, nem toboroz

  Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

  NCT06663787· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák10 toboroz
• Vastagbélrák7 toboroz
• Gyomor- és nyelőcsőrák6 toboroz
• Fej-nyaki daganatok5 toboroz
• Petefészekrák4 toboroz
• Hasnyálmirigyrák3 toboroz
• Áttétes emlőrák2 toboroz
• Tripla negatív emlőrák2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhnyakrák1 toboroz
• Méhtestrák1 toboroz
• Szarkóma1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· 1/2. fázis· Forrás

• Lezárult

  Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

  NCT05399329· Forrás

• Lezárult

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· 3. fázis· Forrás

• Lezárult

  Open-label Study of Surufatinib in Japanese Patients

  NCT05077384· 1/2. fázis· Forrás

• Lezárult

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· 3. fázis· Forrás

• Lezárult

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· 3. fázis· Forrás

• Lezárult

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· 3. fázis· Forrás

• Lezárult

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· 3. fázis· Forrás

• Lezárult

  Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323· 3. fázis· Forrás

• Lezárult

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· 3. fázis· Forrás

Vizsgálati helyszínek

• Aichi Cancer Center12 vizsgálat
• Aichi Cancer Center1 vizsgálat
• Aichi Cancer Center1 vizsgálat
• Aichi Cancer Center46 vizsgálat
• Aichi Cancer Center /ID# 2674711 vizsgálat
• Aichi Cancer Center /ID# 2681241 vizsgálat
• Aichi Cancer Center /ID# 2682371 vizsgálat
• Aichi Cancer Center /ID# 2701131 vizsgálat
• Aichi Cancer Center /ID# 2719781 vizsgálat
• Aichi Cancer Center /ID# 2743321 vizsgálat
• Aichi Cancer Center /ID# 2754791 vizsgálat
• Aichi Cancer Center (Site 0006)1 vizsgálat
• Aichi Cancer Center (Site 0018)1 vizsgálat
• Aichi Cancer Center (Site 0658)1 vizsgálat
• Aichi Cancer Center (Site 0803)1 vizsgálat
• Aichi Cancer Center (Site 0855)1 vizsgálat
• Aichi Cancer Center (Site 1007)1 vizsgálat
• Aichi Cancer Center (Site 1601)1 vizsgálat
• Aichi Cancer Center (Site 1626)1 vizsgálat
• Aichi Cancer Center (Site 2114)1 vizsgálat
• Aichi Cancer Center (Site 2217)1 vizsgálat
• Aichi Cancer Center (Site 2502)1 vizsgálat
• Aichi Cancer Center (Site 2702)1 vizsgálat
• Aichi Cancer Center (Site 2714)1 vizsgálat
• Aichi Cancer Center (Site 2813)1 vizsgálat
• Aichi Cancer Center (Site 3016)1 vizsgálat
• Aichi Cancer Center (Site 3200)1 vizsgálat
• Aichi Cancer Center (Site 3307)1 vizsgálat
• Aichi Cancer Center (Site 3400)1 vizsgálat
• Aichi Cancer Center (Site 3702)1 vizsgálat
• Aichi Cancer Center (Site 4010)1 vizsgálat
• Aichi Cancer Center (Site 4190)1 vizsgálat
• Aichi Cancer Center (Site 5000)1 vizsgálat
• Aichi Cancer Center (Site 5110)1 vizsgálat
• Aichi Cancer Center (Site 5117)1 vizsgálat
• Aichi Cancer Center (Site 9702)1 vizsgálat
• Aichi Cancer Centre1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Vastagbélrák75 munka · 9 vizsgálat
• Gyomor- és nyelőcsőrák59 munka · 11 vizsgálat